NEJM: 提前2年揭盲!吴一龙联合全球和国内284个中心团队,发现手术+精准分型靶向治疗降低早中期肺癌术后83%复发风险

2020-10-29 iNature iNature

在我国,肺癌年度发病人数高达78.4万,肺癌的发病率及死亡率分别占全部恶性肿瘤的20.03% 及26.99%,居恶性肿瘤之首。这使得肺癌治疗科研成果万众瞩目。

在我国,肺癌年度发病人数高达78.4万,肺癌的发病率及死亡率分别占全部恶性肿瘤的20.03% 及26.99%,居恶性肿瘤之首。这使得肺癌治疗科研成果万众瞩目。奥西替尼是表皮生长因子受体(EGFR)突变阳性的晚期非小细胞肺癌(NSCLC)的护理标准疗法, 奥西替尼作为辅助治疗的疗效和安全性尚不清楚。

广东省人民医院、广东省肺癌研究所终身主任吴一龙联合全球和国内284个中心团队在顶级医学期刊新英格兰医学杂志NEJM 在线发表题为“Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer”的研究论文,这项双盲的3期临床试验中,以1:1的比例随机分配了完全切除的EGFR突变阳性NSCLC患者(IB期至IIIA期EGFR突变阳性的NSCLC患者),接受奥西替尼(每天一次80 mg)或安慰剂治疗3年。主要终点是II至IIIA期疾病患者的无病生存(根据研究者评估)。次要终点包括IB至IIIA期疾病患者的总体无病生存期,总体生存期和安全性。

该研究共有682例患者接受了随机分组(奥西替尼组339例,安慰剂组343例)。在24个月时,奥西替尼组90%的II至IIIA期患者和安慰剂组的44%存活且无疾病(疾病复发或死亡的总危险比为0.17)。奥西替尼组89%的患者和安慰剂组中52%的患者在24个月内无病生存(疾病复发或死亡的总体危险比为0.20)。在24个月时,奥西替尼组98%的患者和安慰剂组中的85%存活,并且没有中枢神经系统疾病(疾病复发或死亡的总体危险比为0.18)。

总而言之,该研究发现在IB期至IIIA期EGFR突变阳性的NSCLC患者中,接受奥西替尼的患者的无病生存期明显长于接受安慰剂的患者(针对从IB期到IIIA期的早中期肺癌并有驱动基因突变的患者,如在先期手术切除后通过第三代靶向药物的辅助治疗,他们的肿瘤复发风险将下降83个百分点)。

大约30%的非小细胞肺癌(NSCLC)患者是存在可切除的疾病。对于完全切除的II至IIIA期患者,建议术后进行基于顺铂的辅助化疗。但是,这种疗法仅使疾病复发或死亡的风险降低16%。在5年时,其死亡风险降低5%。在大约5年的中位随访中,疾病复发或手术后死亡的患者比例仍然很高。

表皮生长因子受体(EGFR)突变,例如外显子19缺失(Ex19del)和外显子21密码子p.Leu858Arg(L858R)点突变是NSCLC中常见的致癌驱动突变。EGFR酪氨酸激酶抑制剂(EGFR-TKIs) 是推荐的针对EGFR突变阳性的晚期NSCLC的一线治疗。EGFR-TKIs在晚期疾病患者中的疗效促使人们对其作为可切除疾病的辅助治疗方法进行了研究。研究表明,接受第一代EGFR-TKI辅助治疗的EGFR突变阳性NSCLC切除患者的无病生存期可能比接受辅助化疗或安慰剂的患者更长。

奥西替尼(Osimertinib)是第三代口服EGFR-TKI,有效且选择性地抑制EGFR-TKI致敏和EGFR p.Thr790Met耐药性突变,对NSCLC中枢神经系统(CNS)转移具有疗效。在3期FLAURA试验中, 就无进展生存率和总体生存率而言,奥西替尼优于吉非替尼或厄洛替尼。 这些发现为奥西替尼作为以前未经治疗的EGFR突变阳性(Ex19del或L858R)晚期NSCLC的标准治疗方法提供了支持。

此外,接受奥西替尼的患者发生3级或更高级别不良事件的发生率与接受吉非替尼或厄洛替尼的患者相似,尽管治疗时间更长。奥西替尼在EGFR突变阳性NSCLC晚期患者中的疗效和安全性为该药物作为切除疾病的辅助治疗提供了支持。

ADAURA 3期随机试验评估了奥西替尼与安慰剂相比在完全切除的IB至IIIA期患者中的疗效和安全性,根据医生和患者的选择,辅助化疗后EGFR突变阳性(Ex19del或L858R)NSCLC。独立数据监控委员会计划在2020年4月进行审查后,委员会建议,由于有证据表明有疗效,该试验提前了2年公布(原本拟定在2022年公布的临床数据)。

这项双盲的3期临床试验中,以1:1的比例随机分配了完全切除的EGFR突变阳性NSCLC患者,接受奥西替尼(每天一次80 mg)或安慰剂治疗3年。 主要终点是II至IIIA期疾病患者的无病生存(根据研究者评估)。 次要终点包括IB至IIIA期疾病患者的总体无病生存期,总体生存期和安全性。

该研究共有682例患者接受了随机分组(奥西替尼组339例,安慰剂组343例)。在24个月时,奥西替尼组90%的II至IIIA期患者和安慰剂组的44%存活且无疾病(疾病复发或死亡的总危险比为0.17)。奥西替尼组89%的患者和安慰剂组中52%的患者在24个月内无病生存(疾病复发或死亡的总体危险比为0.20)。在24个月时,奥西替尼组98%的患者和安慰剂组中的85%存活,并且没有中枢神经系统疾病(疾病复发或死亡的总体危险比为0.18)。

总而言之,该研究发现在IB期至IIIA期EGFR突变阳性的NSCLC患者中,接受奥西替尼的患者的无病生存期明显长于接受安慰剂的患者(针对从IB期到IIIA期的早中期肺癌并有驱动基因突变的患者,如在先期手术切除后通过第三代靶向药物的辅助治疗,他们的肿瘤复发风险将下降83个百分点)。

原始出处:

Yi-Long Wu, Masahiro Tsuboi, Jie He,et al.Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1905564, encodeId=9edb190556474, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Mon May 31 17:32:59 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895881, encodeId=2bc8895881b6, content=<a href='/topic/show?id=f31f39333f0' target=_blank style='color:#2F92EE;'>#吴一龙#</a>这项研究证实了<a href='/topic/show?id=b0054454337' target=_blank style='color:#2F92EE;'>#奥希替尼#</a>在<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a>术后<a href='/topic/show?id=e65f93688dc' target=_blank style='color:#2F92EE;'>#辅助治疗#</a>的地位,这一下子,奥希替尼市场多了几十个亿呀!!这是此前任何一个<a href='/topic/show?id=e56199944e0' target=_blank style='color:#2F92EE;'>#靶向药物#</a>都没有完成的事情!, beContent=null, objectType=article, channel=null, level=null, likeNumber=229, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39333, encryptionId=f31f39333f0, topicName=吴一龙), TopicDto(id=44543, encryptionId=b0054454337, topicName=奥希替尼), TopicDto(id=13071, encryptionId=2493130e1a1, topicName=NSCLC), TopicDto(id=93688, encryptionId=e65f93688dc, topicName=辅助治疗), TopicDto(id=99944, encryptionId=e56199944e0, topicName=靶向药物)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Oct 31 16:02:09 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403534, encodeId=0b841403534b9, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sat Oct 31 12:32:59 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035477, encodeId=f70110354e779, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Oct 30 00:32:59 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895527, encodeId=1fc589552e92, content=在, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d925430242, createdName=ms6000000221282830, createdTime=Thu Oct 29 22:00:48 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895523, encodeId=52f28955238a, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=521b1859831, createdName=ms138046322519002, createdTime=Thu Oct 29 21:55:26 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895519, encodeId=6eee895519df, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200925/715f77a9a29d4907967d9aff0401c7dd/e9332ce2f0474cf4bcce214162b301b2.jpg, createdBy=07f32537611, createdName=追逐着, createdTime=Thu Oct 29 21:40:46 CST 2020, time=2020-10-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1905564, encodeId=9edb190556474, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Mon May 31 17:32:59 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895881, encodeId=2bc8895881b6, content=<a href='/topic/show?id=f31f39333f0' target=_blank style='color:#2F92EE;'>#吴一龙#</a>这项研究证实了<a href='/topic/show?id=b0054454337' target=_blank style='color:#2F92EE;'>#奥希替尼#</a>在<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a>术后<a href='/topic/show?id=e65f93688dc' target=_blank style='color:#2F92EE;'>#辅助治疗#</a>的地位,这一下子,奥希替尼市场多了几十个亿呀!!这是此前任何一个<a href='/topic/show?id=e56199944e0' target=_blank style='color:#2F92EE;'>#靶向药物#</a>都没有完成的事情!, beContent=null, objectType=article, channel=null, level=null, likeNumber=229, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39333, encryptionId=f31f39333f0, topicName=吴一龙), TopicDto(id=44543, encryptionId=b0054454337, topicName=奥希替尼), TopicDto(id=13071, encryptionId=2493130e1a1, topicName=NSCLC), TopicDto(id=93688, encryptionId=e65f93688dc, topicName=辅助治疗), TopicDto(id=99944, encryptionId=e56199944e0, topicName=靶向药物)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Oct 31 16:02:09 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403534, encodeId=0b841403534b9, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sat Oct 31 12:32:59 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035477, encodeId=f70110354e779, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Oct 30 00:32:59 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895527, encodeId=1fc589552e92, content=在, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d925430242, createdName=ms6000000221282830, createdTime=Thu Oct 29 22:00:48 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895523, encodeId=52f28955238a, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=521b1859831, createdName=ms138046322519002, createdTime=Thu Oct 29 21:55:26 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895519, encodeId=6eee895519df, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200925/715f77a9a29d4907967d9aff0401c7dd/e9332ce2f0474cf4bcce214162b301b2.jpg, createdBy=07f32537611, createdName=追逐着, createdTime=Thu Oct 29 21:40:46 CST 2020, time=2020-10-29, status=1, ipAttribution=)]
    2020-10-31 lovetcm

    #吴一龙#这项研究证实了#奥希替尼##NSCLC#术后#辅助治疗#的地位,这一下子,奥希替尼市场多了几十个亿呀!!这是此前任何一个#靶向药物#都没有完成的事情!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1905564, encodeId=9edb190556474, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Mon May 31 17:32:59 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895881, encodeId=2bc8895881b6, content=<a href='/topic/show?id=f31f39333f0' target=_blank style='color:#2F92EE;'>#吴一龙#</a>这项研究证实了<a href='/topic/show?id=b0054454337' target=_blank style='color:#2F92EE;'>#奥希替尼#</a>在<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a>术后<a href='/topic/show?id=e65f93688dc' target=_blank style='color:#2F92EE;'>#辅助治疗#</a>的地位,这一下子,奥希替尼市场多了几十个亿呀!!这是此前任何一个<a href='/topic/show?id=e56199944e0' target=_blank style='color:#2F92EE;'>#靶向药物#</a>都没有完成的事情!, beContent=null, objectType=article, channel=null, level=null, likeNumber=229, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39333, encryptionId=f31f39333f0, topicName=吴一龙), TopicDto(id=44543, encryptionId=b0054454337, topicName=奥希替尼), TopicDto(id=13071, encryptionId=2493130e1a1, topicName=NSCLC), TopicDto(id=93688, encryptionId=e65f93688dc, topicName=辅助治疗), TopicDto(id=99944, encryptionId=e56199944e0, topicName=靶向药物)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Oct 31 16:02:09 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403534, encodeId=0b841403534b9, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sat Oct 31 12:32:59 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035477, encodeId=f70110354e779, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Oct 30 00:32:59 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895527, encodeId=1fc589552e92, content=在, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d925430242, createdName=ms6000000221282830, createdTime=Thu Oct 29 22:00:48 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895523, encodeId=52f28955238a, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=521b1859831, createdName=ms138046322519002, createdTime=Thu Oct 29 21:55:26 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895519, encodeId=6eee895519df, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200925/715f77a9a29d4907967d9aff0401c7dd/e9332ce2f0474cf4bcce214162b301b2.jpg, createdBy=07f32537611, createdName=追逐着, createdTime=Thu Oct 29 21:40:46 CST 2020, time=2020-10-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1905564, encodeId=9edb190556474, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Mon May 31 17:32:59 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895881, encodeId=2bc8895881b6, content=<a href='/topic/show?id=f31f39333f0' target=_blank style='color:#2F92EE;'>#吴一龙#</a>这项研究证实了<a href='/topic/show?id=b0054454337' target=_blank style='color:#2F92EE;'>#奥希替尼#</a>在<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a>术后<a href='/topic/show?id=e65f93688dc' target=_blank style='color:#2F92EE;'>#辅助治疗#</a>的地位,这一下子,奥希替尼市场多了几十个亿呀!!这是此前任何一个<a href='/topic/show?id=e56199944e0' target=_blank style='color:#2F92EE;'>#靶向药物#</a>都没有完成的事情!, beContent=null, objectType=article, channel=null, level=null, likeNumber=229, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39333, encryptionId=f31f39333f0, topicName=吴一龙), TopicDto(id=44543, encryptionId=b0054454337, topicName=奥希替尼), TopicDto(id=13071, encryptionId=2493130e1a1, topicName=NSCLC), TopicDto(id=93688, encryptionId=e65f93688dc, topicName=辅助治疗), TopicDto(id=99944, encryptionId=e56199944e0, topicName=靶向药物)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Oct 31 16:02:09 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403534, encodeId=0b841403534b9, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sat Oct 31 12:32:59 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035477, encodeId=f70110354e779, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Oct 30 00:32:59 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895527, encodeId=1fc589552e92, content=在, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d925430242, createdName=ms6000000221282830, createdTime=Thu Oct 29 22:00:48 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895523, encodeId=52f28955238a, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=521b1859831, createdName=ms138046322519002, createdTime=Thu Oct 29 21:55:26 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895519, encodeId=6eee895519df, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200925/715f77a9a29d4907967d9aff0401c7dd/e9332ce2f0474cf4bcce214162b301b2.jpg, createdBy=07f32537611, createdName=追逐着, createdTime=Thu Oct 29 21:40:46 CST 2020, time=2020-10-29, status=1, ipAttribution=)]
    2020-10-30 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1905564, encodeId=9edb190556474, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Mon May 31 17:32:59 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895881, encodeId=2bc8895881b6, content=<a href='/topic/show?id=f31f39333f0' target=_blank style='color:#2F92EE;'>#吴一龙#</a>这项研究证实了<a href='/topic/show?id=b0054454337' target=_blank style='color:#2F92EE;'>#奥希替尼#</a>在<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a>术后<a href='/topic/show?id=e65f93688dc' target=_blank style='color:#2F92EE;'>#辅助治疗#</a>的地位,这一下子,奥希替尼市场多了几十个亿呀!!这是此前任何一个<a href='/topic/show?id=e56199944e0' target=_blank style='color:#2F92EE;'>#靶向药物#</a>都没有完成的事情!, beContent=null, objectType=article, channel=null, level=null, likeNumber=229, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39333, encryptionId=f31f39333f0, topicName=吴一龙), TopicDto(id=44543, encryptionId=b0054454337, topicName=奥希替尼), TopicDto(id=13071, encryptionId=2493130e1a1, topicName=NSCLC), TopicDto(id=93688, encryptionId=e65f93688dc, topicName=辅助治疗), TopicDto(id=99944, encryptionId=e56199944e0, topicName=靶向药物)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Oct 31 16:02:09 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403534, encodeId=0b841403534b9, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sat Oct 31 12:32:59 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035477, encodeId=f70110354e779, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Oct 30 00:32:59 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895527, encodeId=1fc589552e92, content=在, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d925430242, createdName=ms6000000221282830, createdTime=Thu Oct 29 22:00:48 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895523, encodeId=52f28955238a, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=521b1859831, createdName=ms138046322519002, createdTime=Thu Oct 29 21:55:26 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895519, encodeId=6eee895519df, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200925/715f77a9a29d4907967d9aff0401c7dd/e9332ce2f0474cf4bcce214162b301b2.jpg, createdBy=07f32537611, createdName=追逐着, createdTime=Thu Oct 29 21:40:46 CST 2020, time=2020-10-29, status=1, ipAttribution=)]
    2020-10-29 ms6000000221282830

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1905564, encodeId=9edb190556474, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Mon May 31 17:32:59 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895881, encodeId=2bc8895881b6, content=<a href='/topic/show?id=f31f39333f0' target=_blank style='color:#2F92EE;'>#吴一龙#</a>这项研究证实了<a href='/topic/show?id=b0054454337' target=_blank style='color:#2F92EE;'>#奥希替尼#</a>在<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a>术后<a href='/topic/show?id=e65f93688dc' target=_blank style='color:#2F92EE;'>#辅助治疗#</a>的地位,这一下子,奥希替尼市场多了几十个亿呀!!这是此前任何一个<a href='/topic/show?id=e56199944e0' target=_blank style='color:#2F92EE;'>#靶向药物#</a>都没有完成的事情!, beContent=null, objectType=article, channel=null, level=null, likeNumber=229, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39333, encryptionId=f31f39333f0, topicName=吴一龙), TopicDto(id=44543, encryptionId=b0054454337, topicName=奥希替尼), TopicDto(id=13071, encryptionId=2493130e1a1, topicName=NSCLC), TopicDto(id=93688, encryptionId=e65f93688dc, topicName=辅助治疗), TopicDto(id=99944, encryptionId=e56199944e0, topicName=靶向药物)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Oct 31 16:02:09 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403534, encodeId=0b841403534b9, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sat Oct 31 12:32:59 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035477, encodeId=f70110354e779, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Oct 30 00:32:59 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895527, encodeId=1fc589552e92, content=在, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d925430242, createdName=ms6000000221282830, createdTime=Thu Oct 29 22:00:48 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895523, encodeId=52f28955238a, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=521b1859831, createdName=ms138046322519002, createdTime=Thu Oct 29 21:55:26 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895519, encodeId=6eee895519df, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200925/715f77a9a29d4907967d9aff0401c7dd/e9332ce2f0474cf4bcce214162b301b2.jpg, createdBy=07f32537611, createdName=追逐着, createdTime=Thu Oct 29 21:40:46 CST 2020, time=2020-10-29, status=1, ipAttribution=)]
    2020-10-29 ms138046322519002

    继续关注

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1905564, encodeId=9edb190556474, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Mon May 31 17:32:59 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895881, encodeId=2bc8895881b6, content=<a href='/topic/show?id=f31f39333f0' target=_blank style='color:#2F92EE;'>#吴一龙#</a>这项研究证实了<a href='/topic/show?id=b0054454337' target=_blank style='color:#2F92EE;'>#奥希替尼#</a>在<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a>术后<a href='/topic/show?id=e65f93688dc' target=_blank style='color:#2F92EE;'>#辅助治疗#</a>的地位,这一下子,奥希替尼市场多了几十个亿呀!!这是此前任何一个<a href='/topic/show?id=e56199944e0' target=_blank style='color:#2F92EE;'>#靶向药物#</a>都没有完成的事情!, beContent=null, objectType=article, channel=null, level=null, likeNumber=229, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39333, encryptionId=f31f39333f0, topicName=吴一龙), TopicDto(id=44543, encryptionId=b0054454337, topicName=奥希替尼), TopicDto(id=13071, encryptionId=2493130e1a1, topicName=NSCLC), TopicDto(id=93688, encryptionId=e65f93688dc, topicName=辅助治疗), TopicDto(id=99944, encryptionId=e56199944e0, topicName=靶向药物)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Oct 31 16:02:09 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403534, encodeId=0b841403534b9, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sat Oct 31 12:32:59 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035477, encodeId=f70110354e779, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Oct 30 00:32:59 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895527, encodeId=1fc589552e92, content=在, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d925430242, createdName=ms6000000221282830, createdTime=Thu Oct 29 22:00:48 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895523, encodeId=52f28955238a, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=521b1859831, createdName=ms138046322519002, createdTime=Thu Oct 29 21:55:26 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895519, encodeId=6eee895519df, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200925/715f77a9a29d4907967d9aff0401c7dd/e9332ce2f0474cf4bcce214162b301b2.jpg, createdBy=07f32537611, createdName=追逐着, createdTime=Thu Oct 29 21:40:46 CST 2020, time=2020-10-29, status=1, ipAttribution=)]
    2020-10-29 追逐着

    不错

    0

相关资讯

ESMO:50%晚期NSCLC患者可获长达4年生存期 度伐利尤单抗治疗显优异生存获益

肺癌是男性和女性癌症死亡的主要原因,约占所有癌症死亡人数的五分之一。通常,肺癌分为非小细胞肺癌(NSCLC)和小细胞肺癌(SCLC);其中大约85%被认定为非小细胞肺癌,15%为小细胞肺癌。

Thorax:遗传引起的血清胆红素水平升高与肺癌发病率

遗传引起的血清胆红素升高在人群中普遍存在,可以保护暴露于高水平烟雾氧化剂的人群免受肺癌的侵害。

Chest:每年吸烟包数随机测量误差对肺癌筛查决策的影响

在决定是否进行CT筛查时,如果使用吸烟数量≥30包/年的标准,那么每年吸烟数量评估的随机误差会导致大量的患者被错误分类。但是,如果使用肺癌风险阈值则可以减少不可靠吸烟包数信息的影响。

NEJM重磅 :提前2年揭盲!吴一龙联合全球和国内284个中心团队,发现手术+精准分型靶向治疗降低早中期肺癌术后83%复发风险

在我国,肺癌年度发病人数高达78.4万,肺癌的发病率及死亡率分别占全部恶性肿瘤的20.03% 及26.99%,居恶性肿瘤之首。这使得肺癌治疗科研成果万众瞩目。

拒烟有秒招,降低患肺癌风险,抖音公益挑战赛完美收官

为促进社会各界对烟草危害和小细胞肺癌的关注,呼吁大众,尤其是年轻人远离烟草,推进无烟环境建设, 由健康中国行动控烟行动工作组指导,国家呼吸疾病临床研究中心、中国健康教育中心、中国戒烟联盟、中国医学科学

JTO:阿司匹林、他汀类药物和二甲双胍与肺癌风险和相关死亡率的关系

本研究的目的是使用基于人群的全国队列数据研究阿司匹林,二甲双胍和他汀类药物与肺癌风险和死亡率的关系。